Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's afte

Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-

https://ir.biorestorative.com/sec-filings/all-sec-filings/content/0001493152-26-033593/form8-k.htm

Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-mark

BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company")

MELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,”

Accomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development

US stocks mixed, Dow up 300 pts. Dow up 0.64%, NASDAQ down 0.34%. Consumer discretionary up 1.7%, en

Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all sharehol

Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all sharehol

BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company")

Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment admi

Biorestorative Therapies (BRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optim

Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.19 per share versus the Z

Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting

Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting

Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patie

Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patie

BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company")

Data demonstrate progress in each of its MSC-derived programs MELVILLE, N.Y., April 30, 2026 (GLOBE

Biorestorative Therapies (BRTX) appears to have found support after losing some value lately, as ind

Collaboration establishes an independent clinical validation pathway, expands access to influential

Partnership to drive brand architecture, go-to-market execution, and global launch of the Company's

BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company")

Data showed 50% or more of patients reporting >50% improvement in key pain and function scales  No a

Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.32 per share versus the Z

BioRestorative Therapies (NASDAQ:BRTX) reported quarterly losses of $(0.32) per share which missed t

BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company")

New blinded data from ~45 patients to date in key pain and function scales and safety and tolerabili

ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA,

Company to engage industry partners and distribution channels as part of expanding BioCosmeceutical

BioRestorative Therapies, Inc. (OTCMKTS:BRTX - Get Free Report) crossed below its 50-day moving aver

GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, mu

MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”,